This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are “material information” as defined in the Policies. The discussion in this report must be factual, balanced, and non-promotional.

General Instructions

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should question be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title of each item must precede the answer.

2. The term “Issuer” includes the Issuer and any of its subsidiaries.

3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued its business of developing and accelerating the commercialization of its proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor, and assess cancer treatment early, accurately, and cost-effectively. The Company has developed its annual roadmap, continues to hold regular management meetings regarding all aspects of the Company’s business plan, and executes action items that result from these meetings.

Management’s primary areas of focus continue to include:

• Accelerating commercialization efforts of its lab-developed test (LDT) for early lung cancer detection following promising interim retrospective data presented at various oncology conferences across N. America and Europe.

• These results were statistically significant and continued to generate interest from leading institutions in the US, France, Germany and South America which the company intends to pursue post-launching its assay initially in Canada following certification of its Quebec-based lab and data readout on its lung cancer clinical studies.

• Complete data analytics on the large-scale early lung cancer multimodal study (5,400 patients) across 7 hospitals based in Quebec after the successful completion of plasma samples and analysis using BioMark’s metabolomics assay. Preliminary results on cancer confirmed (retrospective) cases are expected by mid 2025. Additional data on prospective lung cancer screening cohort will continue to be collected in 2025 as detailed in the clinical design. Pending the outcome of the results the company intends to present it at a major cancer symposium.

• Preparation for lab certification and accreditation to initially meet international ISO 15189:2022 standard for the Canadian operation and later secure CLIA and CAP accreditation to provide lab services in the U.S. Canadian certification is expected by Q3 of 2025 following recent meetings with certification authorities. The lab team has diligently prepared all necessary documentation for registration, setting up data security infrastructure.

• Seek deeper collaborations with several high-profile USA medical institutions and introduce the company to insurance companies (payers), regulatory experts, advocacy groups, and biopharma partners as its early lung cancer LDT commercialization efforts gather momentum. The US market is strategic due to its large addressable lung cancer screening market for at-risk populations (estimated at over 16 million annually). The market remains mostly untapped as there’s only a 5-6% penetration of image-based screening for the population at risk of developing lung cancer. In addition, the federal government is encouraging expanded accessibility for lung cancer screening initiatives across different states, especially for rural communities that are resource constrained.

• Continue to seek and secure the necessary funding to unlock the full potential of its diagnostic platform. The Company will continue to target non-dilutive funding opportunities from Canadian, European, and U.S. agencies and foundations to support key initiatives, including:

• • Optimizing our lab operations

  • Achieving clinical lab certification

  • Driving U.S. expansion

  • Fueling business development

  • Conducting clinical studies to extend the platform to additional cancers and define its role in treatment response assessment.

2. Provide a general overview and discussion of the activities of management.

• Political tensions with the new US administration and the potential imposition of tariffs continue to create anxiety and uncertainty across the business spectrum. The on and off deadlines pose uncertainty and difficulties in business planning. Recent negotiations have not yielded any positive developments between our respective governments

Tariffs can have a complex and potentially significant impact on Canadian businesses, particularly small diagnostics companies like BioMark. Below is a breakdown of the key areas of concern:

• Increased Costs: Tariffs on imported goods increase the cost of raw materials, components, and finished products. This can lead to higher prices for consumers and businesses. For a diagnostics company, this could mean increased costs for laboratory equipment, reagents, and other essential supplies.

• Supply Chain Disruptions: Tariffs can disrupt established supply chains, leading to delays and shortages.

• Trade Uncertainty: Tariffs can create uncertainty in the marketplace, making it difficult for businesses to plan and invest. This uncertainty can discourage investment and hinder economic growth.

• Increased Operating Costs: Small companies often have limited resources and may struggle to absorb increased costs. This could impact BioMark’s ability to invest in research and development, which is crucial for innovation in the diagnostics industry.

• BioMark operates within a challenging economic environment that significantly impacts small-cap diagnostic companies. Funding landscape shows recovery with continued selectivity. This environment particularly challenges emerging diagnostic companies like BioMark, as investors continue to prioritize clinical-stage companies with proven concepts. A significant positive development has occurred in federal research funding. NIH funding is being restored following federal court intervention, with $2.1 billion in previously terminated grants being reinstated. This restoration creates new opportunities for BioMark’s potential government collaborations and grant applications.

• The talent shortage crisis has expanded beyond cybersecurity to include critical AI capabilities. These shortages directly impact diagnostic companies’ ability to scale operations, maintain regulatory compliance, and implement advanced analytics capabilities essential for next-generation diagnostic platforms. To address these market challenges, BioMark has adopted a partnership-driven strategy that leverages collaborations with organizations possessing established AI capabilities and computing infrastructure with leading institutions. This approach allows the company to access advanced machine learning expertise and computational resources without competing directly for scarce AI talent in the open market. This strategic positioning enables accelerated platform development while mitigating talent shortage risks and positions BioMark to capitalize on the growing intersection of AI and diagnostic technologies.

• BioMark’s strategic collaboration with Harrisburg University under the leadership of Dr. Maria Vaida, Assistant Professor of Data Science, along with Ph.D. student team, created deep learning framework that maps biological signals from blood plasma using metabolites, significantly enhancing our assay performance and diagnostic capabilities. This productive partnership is yielding fruitful outcomes as we integrate cutting-edge artificial intelligence and dynamic machine learning approaches to advance our cancer diagnostic platform and pioneer new frontiers in metabolomics research. Preliminary results for the confirmed case cohort and the expanded non-cancer groups continue to demonstrate very encouraging results. More data analysis is being incorporated, and the collective team plans to publish or present the data at a high-profile event.

• On July 7, 2025, BioMark welcomed the new Director of Quality Assurance, whose extensive experience is directly aligned with our strategic goals for certification, commercialization, and lab optimization. This key appointment will be instrumental in guiding our centralized lab team toward achieving critical accreditation and ISO certification milestones. BioMark is actively planning to expand its technical and core lab team. The search for an additional lab member will begin with interviews and screening in August, with the goal of having the selected candidate join the team by September 2025 or sooner. This proactive step ensures BioMark is well-positioned to support its future growth and operational demands.

• On July 28, 2025, the Company conducted and successfully completed the annual audit with the auditor, MNP LLP – Audited Financial Statement and MD&A filed in SEDAR and Canadian Securities Exchange as required by regulators.

• In July 2025, BioMark began constructing a strategic Expression of Interest (EOI) agreement with a well-established third party to explore the clinical application of BioMark’s innovative liquid biopsy platform for lung cancer detection initially in Tunisia and later across the broader North African region. Future updates will be provided as progress is made.

• On July 30, 2025, BioMark received Notice of Allowance that Chinese Patent Application N° 201980092723., METHOD OF DETECTING LUNG CANCER, has been allowed by the Chinese National Intellectual Property Administration (CNIPA). The patent is expected to be issued shortly.

• In July 2025, BioMark was actively engaged in negotiations with leading third-party vendors to acquire state-of-the-art instrumentation for its laboratory facilities. This strategic lab capacity expansion will significantly expand its analytical capabilities and processing capacity, positioning it to meet growing demand as it continues to establish high-value research and development collaborations with institutional partners across Europe and the USA. The enhanced laboratory infrastructure will enable accelerated sample throughput, improve assay precision, and support multiple concurrent projects – critical factors for scaling its operations and enhancing revenue generation through expanded collaborative partnerships. This instrumentation investment aligns directly with BioMark’s commercialization timeline and supports its ability to deliver on partnership commitments while maintaining the highest quality standards. Further updates will be provided as progress is made.

• BioMark continues to entertain discussions with various financial institutions, accredited individual investors, and government agencies to secure non-dilutive funding, favourable loans, and equity investments to accelerate the commercialization of its early lung cancer liquid biopsy franchise, to advance its expansion strategy in the USA and internationally as well as for general corporate purposes.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements, etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from, or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists, and trademarks.

On July 30, 2025, BioMark received Notice of Allowance that Chinese Patent Application N° 201980092723., METHOD OF DETECTING LUNG CANCER, has been allowed by the Chinese National Intellectual Property Administration (CNIPA). The patent is expected to be issued shortly.

The Issuer continues to file trademarks and patents in specific jurisdictions for all its patents. Review of the filings and opinions from patent offices are being reviewed as needed.

10. Report on any employee hiring, terminations or lay-offs with details of the anticipated length of lay-offs.

On July 7, 2025, BioMark welcomed the new Director of Quality Assurance, whose extensive experience is directly aligned with our strategic goals for certification, commercialization, and lab optimization. This key appointment will be instrumental in guiding our centralized lab team toward achieving critical accreditation and ISO certification milestones.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

Not applicable.

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers, or committee members.

Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

The trends and risks that are likely to impact the Issuer are discussed in the Form 51-102F1 Management’s Discussion & Analysis Annual Report for the Year Ended March 31, 2025.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated August 4^th, 2025